Best Life Sciences Companies in Copenhagen, Denmark
The 188 best Life Sciences companies in Copenhagen, Denmark in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: LEO Pharma.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Copenhagen
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | LEO Pharma 🦄 Developer of drugs for treating dermatology diseases | $561M | 50 mo ago | 77 | Christophe Bourdon CEO | 1,266 patents Patents concentrated in chemistry & materials | — |
| 2 | Hemab 🦄 Developer of preventative treatments for rare bleeding and thrombotic disorders | $190M | 7 mo ago | 10 | — | — | — |
| 3 | IO Biotech Developer of vaccine for the treatment of cancer | $175M | 34 mo ago | 15 15 → 36 (+140%) | Mai-Britt Zocca CEO and Founder | 2 patents Therapeutic vaccines and osteoprotegerin ligand inhibition for bone disease treatment | — |
| 4 | Galecto Biotech Developer of galectin modulators for treating idiopathic pulmonary fibrosis | $160M | 68 mo ago | 29 | Hans Schambye President & CEO | 184 patents Small-molecule galactoside inhibitors targeting galectin proteins for therapeutic use | — |
| 5 | Santaris Pharma Developer of RNA-targeted therapies for infectious and metabolic diseases | $104M | 168 mo ago | 60 | Peter Sondermann Founder & CEO | 516 patents Therapeutic antisense oligonucleotides for TNF receptor modulation and microRNA inhibition | — |
| 6 | Muna Therapeutics Developer of small-molecule therapeutics for neurodegenerative diseases | $102M | 44 mo ago | 16 | Rita Balice-Gordon CEO | 35 patents Immunomodulatory small molecules targeting TREM2 and Kv1.3 for neuroinflammation therapy | — |
| 7 | Antag Therapeutics Developer of peptide-based therapies for obesity and cardiometabolic disorders | $87M | 18 mo ago | — | Alexander Sparre-Ulrich Co-Founder & COO | 39 patents Design and optimization of GIP peptide analogs for metabolic/obesity therapeutics | — |
| 8 | Acesion Pharma Developer of drugs for treating atrial fibrillation | $70M | 32 mo ago | 7 | Morten Grunnet Co-Founder & CSO | 30 patents Patents concentrated in chemistry & materials | — |
| 9 | MedTrace Developer of molecular imaging tools for quantifying blood flow | $66M | 32 mo ago | 17 | Peter Larsen Co-Founder & CTO | 19 patents Safe preparation and infusion systems for short-lived diagnostic radiopharmaceuticals | — |
| 10 | Orphazyme ApS Developer of therapeutics for the treatment of rare and genetic diseases | $59M | 69 mo ago | 141 | Anders Vadsholt CEO | 70 patents Small-molecule Hsp70 inducers and extended-release formulations for protein‑misfolding therapies | — |
| 11 | SNIPR Biome Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely | $54M | 10 mo ago | 48 48 → 46 (-4%) | Morten Sommer Co-Founder | 142 patents Engineered microbial therapeutics and delivery vectors for infection control and stressed cell targeting | 4 job openings |
| 12 | CathVision Provider and developer of an AI-based cardiac ablation therapy software and device | $36M | 35 mo ago | 18 18 → 40 (+122%) | Rune Orndrup Co-Founder | — | 1 launch · 1 expansion |
| 13 | Scandion Oncology Developer of drugs that specifically target chemotherapy resistance mechanisms | $35M | 67 mo ago | 3 | Jan Stenvang CSO and Co-founder of Scandion Oncology | 83 patents Patents concentrated in health & consumer products | — |
| 14 | AFYX Therapeutics Developer of drug patches for the treatment of mucosal diseases | $33M | 81 mo ago | 6 | — | 69 patents Electrospun fiber-based drug delivery systems for nasal, skin, and mucosal administration | — |
| 15 | Orbis Medicines Provider of drug discovery platform to develop multiple therapeutics | $33M | 17 mo ago | 8 | Sevan Habeshian Co-Founder | — | — |
| 16 | Upfront Chromatography Provides chromatography technology for protein separation processes | $32M | 221 mo ago | 5 | — | 118 patents Large‑scale chromatography media and processes for protein and oligosaccharide purification | — |
| 17 | Synklino Developer of drugs for the treatment of chronic viral infections | $32M | 48 mo ago | 5 | Thomas Kledal CEO & Co-Founder | 6 patents Ex vivo organ preservation and perfusion compositions for transplant readiness | 1 award |
| 18 | BioImage Developer of bioassays for biopharmaceutical companies and research institutions | $30M | 292 mo ago | 42 | Fuhui Long Co-Founder | 9 patents Patents concentrated in chemistry & materials | — |
| 19 | ViroGates Developer of biomarkers and diagnostic kits | $28M | 46 mo ago | 9 | Jakob Knudsen CEO | 11 patents Risk assessment and diagnostic methods for SARS‑CoV‑2 infection using medical testing devices | 1 partnership |
| 20 | Action Pharma [Deadpooled] Develops new drugs to treat cardiovascular disease and inflammatory diseases | $28M | 192 mo ago | 1 | — | 57 patents Design of alpha‑MSH peptide analogs and phenyl‑pyrrole aminoguanidine small‑molecule therapeutics | — |
| 21 | Hoba Therapeutics Developer of therapeutics for the treatment of neuropathic pain and hearing disorders | $27M | 30 mo ago | 3 | Kenneth Petersen Founder | 22 patents Analgesic therapeutics for nociceptive and chemotherapy‑induced neuropathic pain | — |
| 22 | Biosyntia Developing biocatalysts using synthetic biology and metabolic engineering technology | $23M | 47 mo ago | 19 19 → 22 (+16%) | Hans Genee Co-Founder and CSO | — | — |
| 23 | EpiTherapeutics Developer of therapies to treat cancer | $23M | 146 mo ago | — | John Milligan CEO & President | — | — |
| 24 | NEUmiRNA Developer of RNA therapeutics for the treatment of neurological disorders | $21M | 17 mo ago | 3 | — | — | 1 partnership |
| 25 | Invert Modern software for bioprocess development and scale-up | $21M | 23 mo ago | 19 | Martin Tromp Permin Co-Founder | — | — |
| 26 | Rivelin Drug delivery platform to deliver a pharmaceutical drug uni-directional to a mucosal surface | $20M | 109 mo ago | 6 | — | — | — |
| 27 | Immudex Provider of immune monitoring reagents and services for research and clinical use | $19M | 16 mo ago | 39 39 → 46 (+18%) | Patrik Dahlen Chief Executive Officer | — | — |
| 28 | Flow Robotics Provider of an AI-based laboratory automation robot system for liquid handling | $17M | 48 mo ago | 28 | Andres Faina Co-Founder | 6 patents Automated laboratory tube handling and scanning robotics for high-throughput testing. | — |
| 29 | Azanta Developer of medicines for orphan oncology and medical device for women's health monitoring | $16M | 128 mo ago | 3 | Claus Juan Moller San Pedro Founder & ex-CEO | 19 patents Oral dispersible tablet formulations, especially misoprostol dosage forms | — |
| 30 | Neurescue Developer of catheter to manage blood flow from other organs to the heart and brain | $15M | 28 mo ago | 9 | Habib Frost Founder & CEO | — | — |
| 31 | BluSense Diagnostics Developer of a next-generation diagnostics platform to diagnose infectious diseases | $14M | 76 mo ago | 35 | — | 5 patents Centrifugal microfluidic platforms for point‑of‑care diagnostic sample processing | — |
| 32 | FluoGuide Developer of surgery targeting drugs for cancer patients | $14M | 47 mo ago | 8 | Andreas Kjaer Founder | 27 patents Fluorophore‑labeled peptides targeting the urokinase plasminogen activator receptor for diagnostic imaging and therapeutic deliver | — |
| 33 | Nuevolution Developer of drug treatments for oncology and chronic inflammatory diseases | $12M | 168 mo ago | 40 | — | 335 patents Design of heterocyclic small‑molecule modulators for nuclear receptors and bromodomain targets | — |
| 34 | Curasight Developer of PET ligands for breast cancer indications | $12M | 68 mo ago | 4 | Carsten Nielsen Co-Founder & Director | 33 patents uPAR-targeted radiolabeled peptides for PET imaging and radionuclide therapy | — |
| 35 | Kvantify Provider of quantum computing solutions for businesses in industries such as finance, life sciences, and… | $11M | 3 mo ago | — | Allan Gronlund Co-Founder & CTO | — | 1 award |
| 36 | VAR2 Pharmaceuticals Developer of therapeutics to treat cancer | $10M | 119 mo ago | 7 | Ali Salanti CEO | 49 patents Targeted antibody therapeutics and drug conjugates for chondroitin sulfate glycans | — |
| 37 | Abzu Provider of a machine learning technology based on quantum mechanics and neural networks | $9M | 44 mo ago | 216 | Casper Wilstrup Founder and Advisory Board Member | — | — |
| 38 | Hervolution Developer of immunotherapies for cancer treatment | $6M | 18 mo ago | 16 16 → 37 (+131%) | — | — | — |
| 39 | Antag Therapeutics Developer of therapeutic peptides for the treatment of obesity | $6M | 60 mo ago | 2 | Alexander Hovard Sparre-Ulrich Co-Founder & CEO | 39 patents Design and optimization of GIP peptide analogs for metabolic/obesity therapeutics | — |
| 40 | Cortrium Provider of an AI and IoT-based ECG monitoring solution | $6M | 68 mo ago | 18 | Erik Poulsen Chief Science Officer | — | — |
| 41 | Evaxion Biotech Developer of immunotherapies for the treatment of cancer and infectious diseases | $5M | 30 mo ago | 61 61 → 51 (-16%) | Andreas Holm Mattsson Co-Founder | 148 patents Personalized neoantigen cancer vaccines and bacterial antigen vaccine design platforms | 1 launch · 1 award |
| 42 | Fuse Vectors Provider of scalable gene therapy manufacturing platform | $5M | 15 mo ago | 3 | Benjamin Blaha Chief Technology Officer | 2 patents In‑vitro production of parvovirus capsids for viral vector gene‑therapy manufacturing | — |
| 43 | Droplet IV Developer of an automatic flushing device for intravenous lines | $5M | 12 mo ago | 8 | Rasmus Falt Co-Founder | — | — |
| 44 | 2cureX Provider of in-vitro tests for precision medicines | $5M | 64 mo ago | 4 | — | 13 patents Patents concentrated in chemistry & materials | — |
| 45 | Inniti Developer of an IoT device for laboratory management | $4M | 61 mo ago | 6 | Anders Rasmussen Co-Founder | — | — |
| 46 | Aioss Provider of personalised health supplement brand | $3M | 18 mo ago | — | Theodor Barington Co-Founder | — | 5 launchs |
| 47 | Alcolase Developer of supplement for the management of alcohol intolerance | $2M | 1 mo ago | 4 | Mads Mikkelsen Co-Founder & CEO | — | — |
| 48 | ABH Optics Developer of lightweight eyeglass lenses | $1M | 22 mo ago | — | Henrik Bense-Petersen Co-Founder | — | — |
| 49 | Vesper Bio Developer of small molecule therapies to treat various diseases | $873K | 28 mo ago | 1 | Mads Kjolby Co-Founder | 28 patents Therapeutic small molecules targeting sortilin for disease modulation | — |
| 50 | BOOST Pharma Developer of stem cell therapies for Osteogenesis Imperfecta | $547K | 7 mo ago | 8 | Cecilia Gotherstrom Co-Founder | — | — |
Top 12 Life Sciences companies in Copenhagen
#1
Hemab 🦄Public · Copenhagen, Capital Region of Denmark · founded 2019 · 10 employees$190Mraised▾
Developer of preventative treatments for rare bleeding and thrombotic disorders. It develops novel therapies designed to modulate the body's clotting pathway, using antibodies to either stabilize or inhibit clotting factors. This approach addresses a significant unmet need for patients with less common disorders, offering prophylactic treatments and potential functional cures to prevent life-threatening complications. The company's pipeline includes several therapeutic candidates targeting various rare clotting disorders.
- Oct 2025Series C$157M
- Feb 2023Series B$135M
- Jul 2021Series A$15M
- Nov 2020Seed$3M
#2
Seed · Copenhagen, Capital Region of Denmark · founded 2022$10.7Mraised▾
Kvantify is a company that provides off-the-shelf, sector-specific solutions for the financial services and life sciences industries. They use cutting-edge algorithms and quantum computing technology to address hard computational challenges. Kvantify aims to democratize access to advanced computing technology and help businesses contribute to a better future.
- Mar 2026Seed$8.1M
- Jul 2024Seed$10.7M
- Feb 2023Grant (prize money)$713K
- Grant (prize money)—
#3
Series B · Copenhagen, Capital Region of Denmark · founded 2011 · 48 employees$53.9Mraised▾
Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely. The company focuses on treating difficult conditions like multidrug-resistant infections, cystic fibrosis, IBD, and certain cancers by engineering the human microbiome.
- Aug 2025Series B$40.6M
- Dec 2024Venture Debt$21.1M
- Jan 2024Series B$11.9M
- Jun 2022Series A$8.4M
#4
Seed · Copenhagen, Capital Region of Denmark · founded 2020 · 4 employees$1.7Mraised▾
Developer of supplement for the management of alcohol intolerance. The company is developing a supplement an oral form, that can degrade ingested alcohol before it hits the bloodstream that aims to help people with alcohol intolerance without experiencing side effects like flushing, rapid heartbeat, and nausea.
- May 2026Seed$1.7M
#5
Series A · Copenhagen, Capital Region of Denmark · founded 2017$87.3Mraised▾
Developer of peptide-based therapies for obesity and cardiometabolic disorders. It offers optimized analogues of naturally occurring GIP receptor inhibitors to induce weight loss and treat obesity without common gastrointestinal side effects.
- Dec 2024Series A$84.1M
- May 2022Seed$503.4K
- Jun 2021Seed$1.6M
- Oct 2018Seed$1.2M
#6
Series A · Copenhagen, Capital Region of Denmark · founded 2009 · 39 employees$19Mraised▾
Provider of immune monitoring reagents and services for research and clinical use. It offers a portfolio of products, including dextramer reagents for flow cytometry and other applications, Klickmer reagents, and custom solutions. The products are used to detect and characterize antigen specific immune cells, supporting research in areas such as vaccine development, cell therapy, and infectious disease. It also provides services such as custom allele production and proficiency testing. Its offerings enable researchers and clinicians to gain a deeper understanding of the immune response in various contexts.It provides a range of products and services such as Dextramer and dcode MHC multimers for detailed immune profiling, clinical grade reagents, monomers and U- Load reagents, techincal and scientfic support, and more.
- Feb 2025Series A$290.6K
- Feb 2024Series A$305.1K
- Mar 2023Series A$245.5K
- Apr 2022Series A$249K
#7
Series A · Copenhagen, Capital Region of Denmark · founded 2022 · 8 employees$32.9Mraised▾
Provider of drug discovery platform to develop multiple therapeutics. The company utilizes novel macrocyclic chemistry and computational platforms for high-throughput drug discovery and develop drug candidates for challenging targets.
- Jan 2025Series A$92.8M
- Feb 2024Seed$32.9M
#8
Series A · Copenhagen, Capital Region of Denmark · founded 2020 · 3 employees$20.8Mraised▾
Developer of RNA therapeutics for the treatment of neurological disorders. The company is pioneering the development of brain-selective RNA medicines for neurological diseases mainly focused on Epilepsy and Parkinson’s Disease.
- Jan 2025Series A$20.8M
- Seed—
#9
Seed · Copenhagen, Capital Region of Denmark · founded 2022 · 8 employees$5Mraised▾
Developer of an automatic flushing device for intravenous lines. The device is a prefilled flushing automation device that uses fluid dynamics principles to help patients receive full dosages. It is integrated with IV bags and lines for IV medicine administration.
- Jun 2025Seed$2M
- 2024Grant (prize money)$3M
#10
Series A · Copenhagen, Capital Region of Denmark · founded 2019 · 8 employees$547.2Kraised▾
Developer of stem cell therapies for Osteogenesis Imperfecta. The company's product line include BOOSTB4 and BOOST2B derived from mesenchymal stem cells targeting children, suffering from Osteogenesis Imperfecta.
- Oct 2025Series A$3.6M
- Mar 2025Seed$621.2K
- Nov 2024Seed$554.9K
- May 2024Seed—
#11
Seed · Copenhagen, Capital Region of Denmark · founded 2022 · 3 employees$5.2Mraised▾
Provider of scalable gene therapy manufacturing platform. The technology utilizes a cell-free AAV filling platform that enables the production of gene therapies at a larger scale for multiple diseases.
- Feb 2025Seed$5.2M
#12
Series A · Copenhagen, Capital Region of Denmark · founded 2021 · 19 employees$20.6Mraised▾
Modern software for bioprocess development and scale-up. The company's software helps in data management, analytics, and modeling in bioprocessing from lab to production, including full process traceability from upstream to formulation.
- Jun 2024Series A$20.1M
- Jan 2022Seed$500K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Copenhagen is moving
A read on the academic research around Biotechnology in Copenhagen — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 107 papers.
Copenhagen's University of Copenhagen and Copenhagen University Hospital lead fungal genetics, yeast biology, and plant pathogen resistance research, with RNA-cancer links emerging, in an optimistic but moderately cautious tone.
- University of Copenhagen96
- Copenhagen University Hospital13
- Copenhagen Business School5
- IT University of Copenhagen1
- University College Copenhagen1
- Genome3
- Metagenomics2
- Microbiome2
- Myxobacteria2
- Geosmin2
- Food processing3
- Bacteria3
- Molecular biology2
- Fermentation2
- Antibiotic resistance2
- Agriculture3
- Quality (philosophy)2
- Rapeseed1
- Glucosinolate1
- PEST analysis1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.